KR100886990B1 - 비정상적인 세포성장의 치료를 위한 피리미딘 유도체 - Google Patents

비정상적인 세포성장의 치료를 위한 피리미딘 유도체 Download PDF

Info

Publication number
KR100886990B1
KR100886990B1 KR1020067023767A KR20067023767A KR100886990B1 KR 100886990 B1 KR100886990 B1 KR 100886990B1 KR 1020067023767 A KR1020067023767 A KR 1020067023767A KR 20067023767 A KR20067023767 A KR 20067023767A KR 100886990 B1 KR100886990 B1 KR 100886990B1
Authority
KR
South Korea
Prior art keywords
ylamino
alkyl
methyl
trifluoromethyl
dihydro
Prior art date
Application number
KR1020067023767A
Other languages
English (en)
Korean (ko)
Other versions
KR20070012477A (ko
Inventor
마이클 조셉 루치오
존 찰스 케이트
Original Assignee
화이자 프로덕츠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100886990(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 프로덕츠 인크. filed Critical 화이자 프로덕츠 인크.
Publication of KR20070012477A publication Critical patent/KR20070012477A/ko
Application granted granted Critical
Publication of KR100886990B1 publication Critical patent/KR100886990B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020067023767A 2004-05-14 2005-05-02 비정상적인 세포성장의 치료를 위한 피리미딘 유도체 KR100886990B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
US60/571,312 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
KR20070012477A KR20070012477A (ko) 2007-01-25
KR100886990B1 true KR100886990B1 (ko) 2009-03-04

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067023767A KR100886990B1 (ko) 2004-05-14 2005-05-02 비정상적인 세포성장의 치료를 위한 피리미딘 유도체

Country Status (27)

Country Link
EP (1) EP1751143A1 (nl)
JP (1) JP4099212B2 (nl)
KR (1) KR100886990B1 (nl)
CN (2) CN1953974A (nl)
AP (1) AP2241A (nl)
AR (1) AR049097A1 (nl)
AU (2) AU2005243397A1 (nl)
BR (1) BRPI0511138A (nl)
CA (1) CA2566707A1 (nl)
CR (1) CR8749A (nl)
EA (1) EA200601796A1 (nl)
EC (1) ECSP066997A (nl)
GE (1) GEP20104875B (nl)
GT (1) GT200500113A (nl)
IL (1) IL178828A0 (nl)
MA (1) MA28583B1 (nl)
MX (1) MXPA06011890A (nl)
NL (2) NL1029045C2 (nl)
NO (1) NO20064576L (nl)
NZ (1) NZ550448A (nl)
PA (1) PA8632601A1 (nl)
PE (1) PE20060240A1 (nl)
TN (1) TNSN06370A1 (nl)
TW (1) TWI303635B (nl)
UY (1) UY28894A1 (nl)
WO (1) WO2005111023A1 (nl)
ZA (1) ZA200608394B (nl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118544A2 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
KR101060051B1 (ko) * 2005-12-21 2011-08-29 화이자 프로덕츠 인크. 비정상적인 세포 성장을 치료하기 위한 피리미딘 유도체
KR101132880B1 (ko) * 2007-04-18 2012-06-28 화이자 프로덕츠 인크. 비정상적인 세포 성장의 치료를 위한 술포닐 아미드 유도체
WO2009012421A1 (en) * 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
ES2645689T3 (es) * 2008-05-21 2017-12-07 Ariad Pharmaceuticals, Inc. Derivados de fósforo como inhibidores de quinasas
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021859A1 (en) * 1997-10-10 1999-05-06 Glaxo Group Limited Azaoxindole derivatives
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US6653308B2 (en) 2001-02-15 2003-11-25 Sugen, Inc. 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AP2385A (en) * 2002-12-20 2012-03-23 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021859A1 (en) * 1997-10-10 1999-05-06 Glaxo Group Limited Azaoxindole derivatives
US6653308B2 (en) 2001-02-15 2003-11-25 Sugen, Inc. 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
CN102127058A (zh) 2011-07-20
CR8749A (es) 2006-12-05
AU2009238255A1 (en) 2009-12-03
PE20060240A1 (es) 2006-04-01
ZA200608394B (en) 2008-05-28
NO20064576L (no) 2006-11-07
UY28894A1 (es) 2005-12-30
GT200500113A (es) 2006-01-10
PA8632601A1 (es) 2006-06-02
NL1029045A1 (nl) 2005-11-15
AU2005243397A1 (en) 2005-11-24
AP2241A (en) 2011-06-01
TW200539871A (en) 2005-12-16
NL1031845C2 (nl) 2006-11-23
JP4099212B2 (ja) 2008-06-11
MA28583B1 (fr) 2007-05-02
MXPA06011890A (es) 2006-12-14
NZ550448A (en) 2010-11-26
JP2007537234A (ja) 2007-12-20
EP1751143A1 (en) 2007-02-14
BRPI0511138A (pt) 2007-11-27
CA2566707A1 (en) 2005-11-24
KR20070012477A (ko) 2007-01-25
TNSN06370A1 (fr) 2008-02-22
WO2005111023A1 (en) 2005-11-24
TWI303635B (en) 2008-12-01
AR049097A1 (es) 2006-06-28
EA200601796A1 (ru) 2007-04-27
GEP20104875B (en) 2010-01-11
NL1029045C2 (nl) 2006-06-02
ECSP066997A (es) 2007-02-28
NL1031845A1 (nl) 2006-07-31
IL178828A0 (en) 2007-03-08
AP2006003790A0 (en) 2006-10-31
CN1953974A (zh) 2007-04-25

Similar Documents

Publication Publication Date Title
KR100886990B1 (ko) 비정상적인 세포성장의 치료를 위한 피리미딘 유도체
US7109337B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EP1625121B1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US7145008B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US7208499B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
KR101060051B1 (ko) 비정상적인 세포 성장을 치료하기 위한 피리미딘 유도체
US20060205945A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130305

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20140211

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20150224

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20160211

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20170221

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20180221

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20190212

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20200214

Year of fee payment: 12